The Relationship Between HIV Infection and Cardiovascular Disease

Birgitt Dau and Mark Holodniy*

*VA Palo Alto Health Care System and Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA, USA

Abstract: Over 30 million people are currently living with human immunodeficiency virus (HIV) infection, and over 2 million new infections occur per year. HIV has been found to directly affect vascular biology resulting in an increased risk of cardiovascular disease compared to uninfected persons. Although HIV infection can now be treated effectively with combination antiretroviral medications, significant toxicities such as hyperlipidemia, diabetes, and excess cardiovascular co-morbidity; as well as the potential for significant drug-drug interactions between HIV and cardiovascular medications, present new challenges for the management of persons infected with HIV. We first review basic principles of HIV pathogenesis and treatment and then discuss relevant clinical management strategies that will be useful for cardiologists who might be involved in the care of HIV infected patients.

Key Words: HIV, cardiology, treatment, natural history, review.

INTRODUCTION TO HIV INFECTION

HIV-1 is an enveloped RNA retrovirus. HIV is transmitted by direct inoculation into the blood stream or after contact and attachment through mucosal surfaces. HIV preferentially infects CD4+ cells. HIV attaches to CD4 and other co-receptors such as CCR5 and CXCR4 on the surface of a cell in order to infect that cell. Within the cell, viral RNA is transcribed to DNA by the HIV reverse transcriptase. Viral DNA then migrates to the cell nucleus and integrates into the host cell genome utilizing the HIV integrase enzyme. The virus can remain latent, or using host factors, initiate viral transcription and translation. The HIV protease enzyme cleaves the viral polyprotein to form mature viral particles, which are then released from the cell to infect other cells. In the absence of HIV treatment, ongoing viral replication and infection of cells leads to CD4+ cell destruction and depletion resulting in immune system dysfunction. Once the CD4 cell count has decreased to < 200/mm3 or < 14%, HIV infection is known as the acquired immunodeficiency syndrome (AIDS). AIDS is manifested by development of opportunistic infections (OIs) and HIV-associated malignancies [1].

After infection the natural history of HIV disease can take several forms and is dependent on underlying host factors and virulence factors associated with different HIV strains. Most people usually have a non-specific viral illness after acute infection. For the majority of the HIV-infected population, a period of chronic (or clinically latent) infection can last years where the immune system is still able to function despite ongoing HIV replication and depletion of CD4 cells. Most HIV infected people require HIV treatment at some point during infection. A small percentage of those infected are able to control viral replication over many years in the absence of treatment and are referred to by various names (i.e., long term nonprogressors, elite controllers). Some develop AIDS relatively quickly and are referred to as rapid progressors. In the absence of HIV treatment, most HIV-infected persons with AIDS develop AIDS complications or death within 2-3 years.

UNAIDS and WHO estimate that approximately 33 million people are HIV infected world-wide and 2.5 million became infected and 2.1 million died of AIDS in 2007 [2]. The major risk factor worldwide for HIV infection is heterosexual contact. In the United States, approximately one million people are infected with HIV, and 25% don’t know they are HIV infected. It is also estimated that about 40,000 new HIV infections occur in the U.S. every year. Although the average age of an HIV-infected person in the U.S. is approximately 30 years, the number of people living with HIV over the age of 50 years is increasing significantly [3]. This reflects the significant decline in HIV-associated mortality as a result of effective HIV treatment.

ANTIRETROVIRAL THERAPY

Six different classes of antiretroviral agents (ARV) have been approved by the U.S. FDA (Table 1). They include: nucleoside reverse transcriptase inhibitors (NRTIs), which block the viral RNA to DNA transcription process; non-nucleoside reverse transcriptase inhibitors (NNRTIs), which inhibit the reverse transcriptase enzyme; protease inhibitors (PIs), which inhibit the viral protease enzyme; fusion inhibitors which block the fusion of HIV with the host cell at the initial point of contact; entry inhibitors which block the entry of HIV into the host cell by blocking the cell-surface co-receptor CCR5; and integrase inhibitors which prevent the integration of the viral DNA into the host genome.

Several national and international expert panels have established numerous HIV treatment guidelines. Recommended regimens usually include three different ARV agents in combination, usually from two classes such as 1 NNRTI + 2 NRTIs or 1 PI + 2 NRTIs [4]. Alternate regimens are also provided in the guidelines for select cases where certain ARV drug classes are contraindicated because of drug interactions, ARV resistance, or severe intolerability to preferred regimens. Ritonavir deserves special mention. Because it can inhibit certain liver cytochrome enzymes and therefore the metabolism of certain PIs, it is now used almost exclusively in small doses to increase the blood levels of other PIs, func-
tioning as a boosting agent. A decision to start treatment is based primarily on the CD4 count level and HIV viral load, and secondarily on the readiness of the patient to accept and adhere to lifelong treatment. In general, treatment is recommended for those patients with a CD4 count < 350/mm³. HIV treatment can fail due to the acquisition of resistant virus by transmission from an exogenous source, or development of ARV resistant virus due to poor adherence or subtherapeutic ARV levels secondary to drug-drug interactions. Although multiple ARVs are available for second line regimens, multidrug resistance can be difficult to treat. The goal of HIV treatment is always to achieve an undetectable HIV viral load (< 50 copies/mL). However, in some patients this may no longer be possible due to acquired ARV drug resistance after several failed regimens. There are no formal guidelines on what specific ARVs are to be used in such situations. Interpretation of genotypic or phenotypic resistance tests and prior ARV history require an experienced HIV expert for optimal management.

**ANTIRETROVIRAL MEDICATION SIDE EFFECTS**

ARVs in general have become easier for patients to tolerate, but a number of symptomatic side effects are still experienced. The most frequent of these is gastrointestinal intolerance, including nausea, vomiting, and diarrhea. These symptoms are commonly seen with lopinavir/ritonavir, ritonavir in combination with any PI, tenofovir, zidovudine,
HIV and Cardiovascular Disease

Table 2. Cardiovascular Associated Adverse Effects of HIV Medications

| Cardiovascular Effects | Antiretroviral: Possibly PIs and other ARVs with unfavorable effects on lipids (e.g. EFV, d4T) |
|------------------------|--------------------------------------------------------------------------------------------------|
| **Onset:** | months to years after beginning of therapy |
| **Presentation:** | premature coronary artery disease |
| **Prevalence:** | 3–6 per 1,000 patient-years |

Other risk factors for cardiovascular disease such as smoking, age, hyperlipidemia, hypertension, diabetes mellitus, family history of premature coronary artery disease, and personal history of coronary artery disease

**Monitoring:** identify hyperlipidemia or hyperglycemia, cardiac risk factors

**Treatment:** Lifestyle modifications: diet, exercise, and/or smoking cessation; switch to agents with less propensity for increasing cardiovascular risk factors, i.e., NNRTI- or ATV-based regimen & avoid d4T use

| Hyperlipidemia | Antiretroviral: All PIs (except ATV); stavudine (d4T); Efavirenz (EFV) (to a lesser extent) |
|----------------|-----------------------------------------------------------------------------------|
| **Onset:** | weeks to months after beginning of therapy |
| **Presentation:** | increased LDL & total cholesterol (TC) & triglyceride (TG), decreased HDL |
| **Prevalence:** | Increased TC & TG – 1.7–2.3x higher in patients receiving (non-ATV) PI; dependent on underlying hyperlipidemia. Risk based on ARV therapy, PI: LPV/r & RTV -boosted PIs > NFV & APV > IDV > ATV; NNRTI: EFV more common than NVP; NRTI: d4T most common |
| **Monitoring:** | Fasting lipid profile at baseline, 3–6 months after starting new regimen, then annually or more frequently if indicated (in high-risk patients, or patients with abnormal baseline levels); Follow HIVMA/ACTG guidelines for management; Assess cardiac risk factor |
| **Treatment:** | Lifestyle modification: diet, exercise, and/or smoking cessation; Switching to agents with less propensity for causing hyperlipidemia; Pharmacologic Management: total cholesterol, LDL, TG 200–500mg/dL: “statins” – pravastatin or atorvastatin; TG >500mg/dL: gemfibrozil or micronized fenofibrate. Use non-PI, non-d4T based regimen; Use ATV-based regimen. |

| Insulin Resistance/ Diabetes Mellitus | Antiretroviral: All PIs |
|--------------------------------------|-------------------------|
| **Onset:** | weeks to months after beginning of therapy |
| **Presentation:** | Polyuria, polydipsia, polyphagia, fatigue, weakness; exacerbation of hyperglycemia in patients with underlying diabetes |
| **Prevalence:** | Up to 3%–5% of patients developed diabetes in some series |
| **Monitoring:** | Fasting blood glucose 1–3 months after starting new regimen, then at least every 3–6 months |
| **Treatment:** | Diet and exercise; use PI-sparing regimens, consider switching to an NNRTI-based regimen; Metformin; “Glitazones”; Sulfonylurea; Insulin |

Adapted from Table 18b, HHS guidelines January 29 2008 [4].

didanosine, abacavir and raltegravir. Efavirenz is associated with central nervous system effects, including vivid dreams, hallucinations, insomnia, and somnolence. Some of the older NRTIs, such as didanosine and stavudine, are associated with peripheral neuropathy.

Atazanavir is associated with asymptomatic hyperbilirubinemia, while nevirapine may cause fatal hepatic necrosis. Maraviroc, tipranavir, and darunavir can all cause hepatotoxicity, particularly in those patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) co-infection. Pancreatitis is seen most often with stavudine and didanosine. A life threatening lactic acidosis can be seen with any NRTI, but most commonly with stavudine. Stevens-Johnson syndrome can be caused by nevirapine, and abacavir can cause a fatal hypersensitivity reaction characterized by fever, rash, malaise, fatigue, anorexia, and shortness of breath. Zidovudine may cause bone marrow suppression, and tenofovir frequently causes renal dysfunction, but can cause acute renal failure as well. The PIs are associated with osteonecrosis, and a resultant increase in hip fractures has been reported [5].

Many ARVs cause hyperlipidemia or the lipodystrophy syndrome, which is manifested by peripheral fat wasting (lipatrophy) and visceral fat accumulation (lipohypertrophy) (Table 2) [6, 7]. This is a class effect of the PIs, and also occurs frequently with the NRTIs, in particular stavudine [8]. The NRTIs are also associated with hepatic steatosis related to mitochondrial toxicity (dysfunction and reduction of mitochondria), most commonly with stavudine and didanosine. Of the NRTIs, stavudine mainly causes increased triglycerides (TG), but may also increase low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC). Of the NNRTIs, efavirenz is more likely to cause hyperlipidemia than nevirapine. All of the PIs except atazanavir have been associated with hyperlipidemia. PIs, and in particular ritonavir-boosted PIs, cause elevations of LDL, TC and TGs and a decrease in high density lipoprotein cholesterol (HDL-C) [9]. PIs suppress the breakdown of transcription factors
such as nuclear sterol regulatory element binding proteins (nSREBPs), which are important in lipid homeostasis [10-12]. This leads to accumulation of nSREBP in the liver, causing increased cholesterol and fatty acid synthesis, and reduced triglyceride storage, leading to increased circulating lipids, and in the tissues, causing lipodystrophy and insulin resistance. PIs also inhibit the breakdown of apolipoprotein B via binding to a region homologous to HIV-1 protease, thereby causing excess production and circulation of triglyceride-rich lipoproteins [11]. The inhibition of cytochrome P450, in particular by ritonavir, may also disrupt fat metabolism by inhibiting the conversion of retinoic acid to cis-9-retinoic acid, which results in reduced stimulation of the retinoic X receptor (RXR). This in turn prevents adipocyte differentiation and increases adipocyte apoptosis, leading to hyperlipidemia [13]. PIs may also bind to HIV-1 protease homologous regions on two proteins important for lipid metabolism, cytoplasmic retinoic-acid binding protein type 1 (CRABP-1) and low-density lipoprotein-receptor-related protein (LRP) [14]. CRABP-1 prevents binding with retinoic acid and RXR action just as cytochrome P450 does, resulting in hyperlipidemia [13]. LRP is responsible for chylomycin clearance in the liver, and for breakdown of triglycerides in the circulation. Therefore PI binding to LRP also contributes to hyperlipidemia [13].

The metabolic side effects of ARVs have been some of the most difficult to manage. The metabolic syndrome, comprised of abdominal obesity, hyperglycemia, dyslipidemia, and hypertension, is associated with PI therapy. The National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III definition of metabolic syndrome is at least 3 of the following risk factors: waist circumference > 88 cm (women) or > 102 cm (men); blood pressure > 130/85 mm Hg or drug treatment for hypertension; triglycerides > 150 mg/dL; fasting glucose > 100 mg/dL; and HDL cholesterol < 50 mg/dL in women or < 40 mg/dL in men [15]. The INITIO study followed patients on NNRTI or PI-based therapy [16]. Of 881 patients in the study, 234 (or 12 per 100 patients-years) developed the metabolic syndrome according to NCEP-III criteria during 3 years of follow-up. For patients who developed the metabolic syndrome during therapy, the hazard ratio of developing cardiovascular disease was 2.73, and the hazard ratio for developing type 2 diabetes mellitus was 4.89. Those patients assigned to PI therapy were more likely to develop the metabolic syndrome on multivariate analysis. Another study found that the incidence of metabolic syndrome was 14% in HIV-infected adults, and was associated with increased levels of leptin and C-reactive protein (CRP), and decreased levels of adiponectin [17].

Type II diabetes has an incidence of 4.4 cases per 1000 person-years of follow-up in HIV-infected patients in the Swiss HIV Cohort [18]. In the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, DM incidence increased with cumulative exposure to ARVs, and was significantly associated with exposure to stavudine, lamivudine, and didanosine [19]. In a group of minority patients in Los Angeles taking PIs, the incidence of diabetes was 7.2% in 3 years of follow-up [20]. In vitro studies demonstrated that the PI indinavir inhibits the activity of GLUT-4, an insulin-sensitive glucose transporter responsible for glucose uptake into muscle and fat cells, thereby contributing to insulin resistance [21, 22]. One PI, atazanavir, did not inhibit GLUT-4 in vitro, which helps to explain some of the clinical data showing less insulin resistance in patients taking atazanavir compared to other PIs. Healthy volunteers taking atazanavir have normal rates of glucose disposal, while those taking lopinavir/ritonavir have decreased glucose disposal [23]. Insulin sensitivity was unchanged in healthy volunteers taking atazanavir/ritonavir 300/100 mg once daily, but was significantly decreased in volunteers taking lopinavir/ritonavir 400/100 mg twice daily [24]. Increasing length of exposure to NRTIs is associated with insulin resistance as well. In the Multicenter AIDS Cohort Study, cumulative exposure to NRTIs was associated with fasting hyperinsulinemia while PIs and NNRTIs, surprisingly, were not [25]. Of all the ARVs, stavudine was associated with the highest risk of hyperinsulinemia, and in another study of healthy volunteers, stavudine administration for one month significantly reduced insulin sensitivity [26].

**DRUG INTERACTION ISSUES IN HIV MANAGEMENT**

In general, NNRTIs and PIs are metabolized in the liver and can inhibit or induce hepatic P450 cytochrome enzymes. In particular, CYP3A4, 2D6, 2C9, 2B6, and 2C19, could be induced or inhibited by various ARVs. Ritonavir is generally a potent inhibitor of 3A4 and 2D6, but can induce 2C9. Other PIs or NNRTIs could have opposite effects. Thus, metabolism of a number of non-HIV related medications can be affected by, or directly affect HIV medications through drug-drug interactions leading to either significant toxicity or decreased efficacy of the target medications. Because of similar metabolic pathways several CV drugs are contraindicated or must be used with caution in patients receiving certain HIV medications (Table 3). The statins simvastatin, and to a lesser extent lovastatin, are metabolized via CYP3A4. Fluvasatin is metabolized via CYP2C9. Rosuvastatin is minimally metabolized via CYP2C9 and CYP2C19, and is largely excreted in the stool non-metabolized. Pravastatin undergoes glucuronidation in the liver, and is renally excreted non-metabolized. Protease inhibitors and the NNRTI delavirdine inhibit CYP3A4, and therefore significantly increase levels of simvastatin and lovastatin [27]. NRTIs are not known to interact with statins. Because the NNRTIs nevirapine and efavirenz both induce CYP3A4, they decrease the AUC of statins. Fibrates do not have significant interactions with ARVs. Other drugs such as bepridil, flecainide, propafenone, quinidine, and amiodarone should not be used with certain ARVs because of common metabolic pathways.

Hepatic metabolism of other drugs such as warfarin, calcium channel blockers, and phosphodiesterase type 5 (PDE5) inhibitors (particularly in combination with nitrates) may be inhibited to a lesser degree and should be used with caution. Potential drug interactions exist between calcium channel blockers, in particular amlodipine, nifedipine, and verapamil, with PIs and NNRTIs, where levels of calcium channel blockers may be significantly increased. Thus, the dose of the calcium channel blockers may need to be reduced [29]. Carvedilol interacts with both PIs and NNRTIs, and caution should be used when co-administering it with these drugs [29]. Beta blockers should be used with caution with ata-
zanavir due to the possibility of additive prolongation of the PR interval [29]. It is safe to use atenolol with atazanavir in the absence of ritonavir. No PR prolongation was found in a clinical study of atazanavir, but the QRS interval was increased an average of 5 ms [30]. There are no specific contraindicated drug-drug interactions between antidiabetic medications and antiretrovirals, however additional monitoring may be necessary due to overlapping medication toxicities (e.g., thiazolidinediones/PIs and liver toxicity, metformin/NRTIs and lactic acidosis). Providers should also watch for potential drug-drug interactions between thiazolidinediones and NNRTIs or protease inhibitors, which could result in increased effects of the hypoglycemic agent. Adjust dosages of these antidiabetic drugs as needed. Some PIs (ritonavir, nelfinavir) can increase glucuronidation of fibrates, thus decreasing their effectiveness. Therefore, cardiologists should always look at metabolic pathways when prescribing new medications, particularly to those HIV infected patients who are already receiving ARVs.

### Table 4. Drug Interactions Between Statins and ARVs Requiring Caution, Monitoring for Toxicity, and Possibly Dose Adjustment

| ARV         | Lipid Lowering Agent† |
|-------------|------------------------|
|             | Atorvastatin           | Pravastatin | Simvastatin or Lovastatin |
| Atazanavir  | Levels may increase. Start with 10 mg. | No data. | Contraindicated. |
| Fosamprenavir| AUC increased 150%. Start with 10 mg. | No data. | Contraindicated. |
| Lopinavir/r | AUC increased 5.9 fold. Start with 10 mg. AUC increased 33%, no dose adjustment necessary. | Contraindicated. |
| Darunavir/r | 10 mg dose gives 40mg exposure. Start with 10 mg. AUC increased 81%, but up to 5 fold. Use lowest starting dose. | Contraindicated. |
| Nelfinavir  | AUC increased 74%. Start with 10 mg. | No data. | Contraindicated. |
| Saquinavir/r| Levels increased 450%. Start with 10 mg. Levels decreased 50%. Use standard dose, adjust based on lipids. | Contraindicated. |
| Tipranavir/r| AUC increased 9 fold. Start with 10 mg. | No data. | Contraindicated. |
| Efavirenz   | AUC decreased 43%. Start with 10 mg, adjust dose based on lipid responses. Levels decreased 40%. Use standard dose, adjust dose based on lipids. Simvastatin AUC decreased by 58%. | No data. | No data. |
| Etravirine  | Decreased AUC 37%. Start with 10 mg, adjust dose based on lipid response. No change for pravastatin, but increased fluvastatin levels may require dose adjustment. | No data. | Decreased levels. |
| Nevirapine  | No data. | No data. | No data. |

Adapted from Table 21, HHS guidelines, January 29, 2008 [4].

† Standard dose rosuvastatin can be used with all ARVs.
In addition to general metabolic alterations, individual patient variation as a result of polymorphic differences in a variety of genes associated with absorption, distribution, metabolism, and excretion (ADME) of medications has been described. For example, alterations in CYP2B6 (AA 516 T/T genotype) have resulted in increased efavirenz plasma concentrations compared to those without this genotype. The HLA-B5701 haplotype has been associated with abacavir hypersensitivity reactions. And active drug transporters such as P-glycoprotein (MDR1) polymorphisms, have also been associated with altered drug transport [31]. Finally, polymorphisms of ABCA1, APOA5, APOC3, APOE, and CETP have been associated with increased lipid levels in HIV-infected patients using ARVs [32].

PATHOPHYSIOLOGY OF HIV-ASSOCIATED CARDIOVASCULAR DISEASE

Chronic inflammation, hypercoagulability and platelet activation all contribute to endothelial dysfunction, and are a probable link between HIV and cardiovascular disease. HIV influences endothelial function via activated monocytes and resultant cytokine secretion, and via a direct effect of the secreted HIV proteins tat and gp120. A simple measure of the chronic inflammation in HIV-infected patients is the higher levels of high sensitivity C-reactive protein (CRP) found in HIV-infected patients compared to control subjects, indicating a higher risk for cardiovascular events [33]. Other inflammatory markers such as interleukins are also elevated in HIV infection. Endothelial markers are increased as well, including soluble vascular cell adhesion molecule (sVCAM-1), soluble intercellular adhesion molecule (sICAM-1), and von Willebrand factor (vWF) [34]. These markers indicate chronic endothelial activation and subsequent endothelial dysfunction, which may trigger inflammation and a hypercoagulable state. Endothelial activation also triggers platelet activation, which can upregulate adhesion molecules.

Much is known about the direct effects of HIV on endothelial function. For example, it is known that nitric oxide (NO) is a mediator of endothelial dysfunction in HIV infection. NO is produced in excess because of reduced expression of endothelial NO synthase (eNOS) and the resultant increased expression of an inducible NO synthase (iNOS) [35]. Then excess NO reacts with oxygen radicals to produce peroxynitrite, which then causes oxidative damage to the vascular endothelium, and decreased flow mediated dilation [36]. The HIV transactivator of viral replication (tat) protein has been shown to significantly decrease eNOS mRNA and thus impair vasorelaxation in porcine coronary arteries [37]. The HIV surface protein gp120 (envelope glycoprotein) also stimulates NO production in activated macrophages, and directly activates endothelial cells resulting in increased adhesion of leukocytes to the endothelium, causing endothelial damage [38, 39]. Clinical evidence of a link between NO and cardiovascular disease was found in a study of HIV-associated cardiomyopathy. Levels of TNF-α and iNOS were significantly higher in HIV-positive individuals with cardiomyopathy on endomyocardial biopsy than in HIV-negative cardiomyopathy patients [40].

The HIV tat protein activates mononuclear cells to secrete cytokines IL-6, IL-8, and TNF-α, which activate endothelial cells and enhances leukocyte adhesion [39]. Both IL-6 and IL-8 are increased in HIV-infected patients and increased levels are correlated with HIV viral load as well as Von Willebrand Factor (vWF), and tissue-type plasminogen activator [41]. HIV tat protein further activates endothelial cells by increasing expression of adhesion molecules that enhance leukocyte adhesion to endothelium [39]. ICAM and VCAM are induced by tat in vascular endothelial cells in vitro [42]. ICAM and VCAM levels are increased in HIV-infected patients, and decrease with ARV treatment [34].

Other effects of HIV infection include increases in IFN-γ, which has been associated with hypertiriglyceridermia [9, 43]. HIV has also been found to lower HDL-C and increase TG; and during progression to AIDS, LDL-C decreases [44]. Adhesion molecules such as E-selectin and Von Willebrand Factor, which promote the endothelial adhesion of platelets, are also increased in HIV infection [39]. Platelet activation is increased via vWF in HIV infection, contributing to an increased incidence of thromboembolic events [45]. Activated coagulation factors and reduced anticoagulants also are important in contributing to thromboembolic events in HIV infection. Activation of coagulation mechanisms may occur through endothelial activation and inflammation [34]. The HIV envelope protein gp120 has been shown in vitro to activate smooth muscle cells via the chemokine receptors CXCR4 and CCR5, and thus to cause them to express tissue factor [46]. Tissue factor, in turn, initiates the coagulation cascade leading to thrombosis. Coagulation abnormalities in HIV include decreases of protein S levels by 73%; increased levels of antithrombin III, and decreased levels of antithrombin are also seen [39, 47].

Finally, HIV-induced apoptosis is another mechanism of endothelial injury. HIV Gp120-induced apoptosis has been implicated in lung endothelial injury contributing to pulmonary hypertension, and HIV tat has been associated with endothelial apoptosis in vitro [39]. Taken together, it is clear that HIV abnormally affects many aspects of cardiovascular physiology.

Many studies have evaluated the effect of HIV on endothelial function, using endothelial function as a proxy for cardiovascular risk. Endothelium-dependent vasodilatation, as measured by flow-mediated dilation (FMD) of the brachial artery, was significantly diminished in 75 HIV infected patients compared to HIV-uninfected controls in a multivariate analysis study [35, 48]. In this study, smoking, male sex, and obesity were also independently linked to decreased FMD, which is a reminder of the association of smoking and obesity with endothelial dysfunction, and the importance of addressing these risk factors in HIV-infected patients. PI therapy was not an independent risk factor for endothelial dysfunction. In a separate study, 22 HIV-infected patients taking PIIs did have impaired FMD compared to 15 HIV-infected patients not taking PI therapy. The group taking PIIs had significantly higher levels of chylomicron, VLDL, LDL, and HDL cholesterol levels, which likely contributed to the endothelial dysfunction seen [49]. A study in rats examined whether the NRTI zidovudine (AZT) causes endothelial dysfunction. AZT alone, and AZT plus indinavir both decreased vessel relaxation [50]. Therefore NRTIs and PIIs may both play a role in the endothelial dysfunction seen in HIV-infected patients. However, since ARVs reduce the endothe-
lial activation caused by uncontrolled HIV infection, their overall effect on endothelial function is still an area of active research and controversy [51].

CARDIOVASCULAR EPIDEMIOLOGY OF HIV INFECTION

Premature coronary artery pathology has been reported among HIV-positive individuals. Autopsy studies first suggested an association between vascular endothelial pathology and HIV [52]. Reporting of clinically evident coronary artery disease (CAD) has increased since the introduction of PIs in 1996. HIV infected patients have higher rates of MI than non-HIV infected patients, 11.13 versus 6.98 per 1000 person-years in a recent US study [53]. A recent Danish study found that HIV infected patients receiving highly active antiretroviral therapy (HAART) were more likely to be hospitalized with ischemic heart disease than HIV-uninfected controls [54]. Similarly, a Kaiser Permanente study found a higher rate of cardiovascular events in HIV infected patients who were not receiving ARV therapy compared to HIV-uninfected controls [55].

Several large studies have compared rates of CAD among HIV-positive patients who are taking PIs compared to those who are not. The HIV Outpatient Study (HOPS) found increased frequency of MIs after the introduction of PIs (p=0.0125), and a hazard ratio of 7.13 by univariate analysis for myocardial infarction in those who used PIs [56]. The hazard ratio on multivariate analysis was 6.51 but did not reach significance. Corroborating this finding was an Italian study that found patients who received PIs had an annual coronary event rate of 5.1/1000 while those who received NNRTIs had an event rate of 4.4/1000 (P<0.001) [57]. Another study using data from the HOPS study and other outpatient clinics found event rates of 9.8/1000 and 6.5/1000 for patients who had and had not been exposed to PIs, respectively (p=0.0008) [58]. A study of the French Hospital Database found an increase in the relative risk of MI with increasing length of time on PI therapy [59]. In a follow-up study combining data from HOPS and the Athena national cohort in the Netherlands, an increased risk of MI was found in those on PI therapy (hazard ratio 1.19, P= 0.04), but not on NNRTI therapy [60]. However, a reduction in a combined endpoint of death and atherosclerotic events of patients on NNRTI or PI-based therapy compared to patients not on therapy was found, underscoring the importance and positive benefits of HAART.

The D:A:D study also found that the incidence of MI increased with length of time on HAART, with an adjusted relative risk of 1.26 (26%) per year of exposure, though the absolute incidence of cardiac events was low at 3.5 per 1000 person-years [61]. A subsequent analysis of the D:A:D study separating the effect of PIs versus NNRTIs found that patients taking PIs had an increased relative risk of MI of 16% per year, while the risk of MI for patients taking NNRTIs was not significantly increased [62, 63]. When adjusted for lipid levels, diabetes mellitus, and hypertension, the relative risk of MI per year was increased only 10%, suggesting that lipid changes accounted for some, but not all, of the risk associated with PI therapy. Another recent finding from the D:A:D study is that abacavir and didanosine were independent risk factors for MI. Recent use of abacavir or didanosine, regardless of duration of use, was associated with a 90% and 49% increased risk of MI, respectively. Zidovudine, stavudine, and lamivudine were not associated with increased risk of MI [64].

However, it is important to remember that the increase in absolute risk attributable to PIs is small. It should be emphasized that the significance of an increased risk of CAD is dependent on the patient's underlying cardiac risk factors. Since risk of CAD is increased by a factor of 1.16 per year of PI therapy, or a doubling of risk over a 5-year period, PIs will confer minimal increased risk to someone with a low starting risk of CAD [65]. The importance of addressing underlying cardiac risk factors, such as tobacco use, must be emphasized. Some of the effects of PI therapy, such as dyslipidemia and insulin resistance, can be medically managed to further reduce CV event risk.

Other studies have reported a decrease in CV risk in patients receiving ARV therapy. HAART appeared to decrease the risk of cardiac disease in the Strategies for Management of Antiretroviral Therapy (SMART) study. Patients in the ARV-sparing arm had an increased rate of cardiac events compared to those who remained on HAART [66]. The increased rate of cardiac events could be related to the increase in inflammation caused by rising HIV viral loads in patients who stopped HAART. A recent study looked at this possibility, and found significantly increased levels of IL-6 (30% versus 5%) and D-dimer (16% versus 0%) in patients who discontinued HAART compared to those who continued HAART [67]. These increased levels of IL-6 and D-dimer were associated with cardiovascular events. A similar treatment interruption study, the STACCATO trial, found increased sVCAM, adiponectin, and IL-10 in the patients who had a treatment interruption versus those who stayed on ARV therapy [68]. Another treatment interruption study found that increases in viral load correlated with increases in sVCAM [69]. Corroborating the beneficial effects of HAART on cardiovascular risk, a large retrospective U.S. Department of Veterans Affairs (VA) study found that the admission rate for cardiovascular and cerebrovascular disease decreased from 1.7 to 0.9 per 100 patient-years from 1995 to 2001, during the time that HAART with ritonavir-boosted protease inhibitors became widely used. No association was found between cardiovascular events and the use of PIs, NNRTIs, or NRTIs [70]. The mean follow-up time was 15 months, and the mean time on PIs was 16 months, so this study may speak more to the short-term benefits of ARV treatment rather than the long term cardiovascular effects of HAART. Overall, these data on the incidence of CAD and MI in HIV-infected individuals support an initial decrease in cardiac risk with the use of ARV therapy, related to a reduction in inflammation and endothelial dysfunction caused by HIV. They do point to an increased cardiovascular risk in those on PI-based therapy, which increases with time spent on therapy.

HIV and HAART have also been associated with increased carotid artery intima-media thickening, which is used as a surrogate for cardiovascular risk. Baseline intima-media thickness (IMT) is higher in patients with HIV infection than those without, and progresses at a faster rate [33, 34].
Increased IMT is associated with classic cardiovascular risk factors, such as older age, higher LDL cholesterol, smoking pack-years, and hypertension. ARV therapy has also been implicated; Jerico et al. found that ARV therapy was associated with subclinical atherosclerosis [72]. Along with PI exposure, lower CD4 count and genetic polymorphisms are also associated with progression of IMT [73, 74]. One of these genetic polymorphisms is in the monocyte chemoattractant protein-1 gene (MCP-1-2518G), and is associated with increased expression. MCP-1 attracts circulating monocytes to endothelial cells where they become foam cells which lodge in the endothelium and contribute to atherosclerosis [74, 75]. Mutations of stromal derived factor-1, (SDF1), which is a chemokine receptor upregulating chemotaxis and adhesion, were shown to cause platelet activation in atheromas, migration of smooth muscle cells to the endothelium, increased expression of CX3CR1, and were associated with lower IMT increases [74]. Another study that found higher carotid IMT in HIV-infected subjects compared to controls was independently associated with cytomegalovirus (CMV)-specific T-cell responses in the HIV-infected population [76]. Carotid IMT has also been found to be higher in HIV-infected children [77]. Other studies have found no association between HIV infection or PI therapy and IMT or IMT progression [78, 79]. However, the baseline IMT in these studies was much lower than other studies, suggesting a lack of sensitivity in detecting IMT changes [80]. It is most likely that HIV and PI therapy both increase IMT, but that the factors most important in determining atherosclerotic disease are traditional risk factors.

Left ventricular dysfunction, dilated cardiomyopathy, and myocarditis all occur with increased frequency in AIDS patients. In a pre-HAART study, global LV hypokinesis was found in 14.5% of patients and was associated with lower CD4 counts, and congestive heart failure was diagnosed in about 2% of patients [81]. Causes may include a direct effect of HIV, other cardiotropic viruses, ARV toxicity, cytokines, opportunistic infections (OIs), illicit drug use, or nutritional deficiencies. In a pre-HAART series of myocardial biopsies in HIV patients, 5 of 33 stained positive for HIV while 16 of 32 were positive for CMV using antisense riboprobes [82]. The incidence of cardiomyopathy is declining post-HAART [83]. Myocarditis has many causes in HIV-infected patients, though a specific diagnosis is rare. These include toxoplasmosis, tuberculosis, Cryptococcus neoformans, Aspergillus, Candida, cytomegalovirus, HSV, Mycobacterium avium intracellulare, and HIV [84, 85]. In an Italian study, lymphocytic interstitial myocarditis was documented in 30 of 440 (7%) of AIDS patients at autopsy [86]. Again, the incidence of myocarditis has also declined in the era of effective HIV treatment.

Pericardial disease is common in HIV-infected patients. In the Prospective Evaluation of Cardiac Involvement in AIDS (PRECIA) study, before the introduction of HAART, the incidence of pericardial effusion was 11% per year, and it was associated with shorter survival and lower CD4 counts [87]. A majority of the effusions were asymptomatic and idiopathic. They rarely cause tamponade [85]. Various OIs and malignancies have been reported to cause pericardial effusions, including Kaposi’s sarcoma, mycobacteria, CMV, prosthetic valve endocarditis, bacterial pericarditis caused by organisms such as Streptococcus pneumoniae [88], Nocardia [89, 90], lymphoma, and immune reconstitution inflammatory syndrome secondary to Mycobacterium tuberculosis (TB) [91]. In Africa, the majority of pericardial disease in HIV infected patients is caused by TB [84, 92, 93]. The incidence of pericarditis has also been decreasing since the introduction of HAART. In a retrospective study of the incidence of cardiac disease comparing the era of mono or dual NRTI therapy versus HAART, the incidence of pericarditis had decreased from 13.5% to 3.4% [83]. Bundle branch block, atrial fibrillation, ischemia, and dilated cardiomyopathy have similarly decreased. It is unknown if the incidence of pericardial effusion has declined in the HAART era. However, the direct effects of HIV and OIs on cardiovascular tissue and the associated cardiac disease have been significantly reduced as a result of effective HIV treatment.

Thromboembolic disease has a high prevalence in HIV-infected patients, including deep vein thrombosis, pulmonary embolism, thrombotic microangiopathy, and retinal venous thrombosis [39]. A retrospective review found a rate of deep venous thrombosis ten times that of HIV-uninfected patients in the general population [94]. Thromboembolic events have been found to occur at higher rates in patients with a CD4 count <200/mm3 compared to those with a CD4 >200/mm3 [95]. Fultz at all looked at a 37,535 HIV-infected veterans and the same number of controls, and found an increased rate of venous thromboembolism in the HIV-infected veterans both before 1996, in the pre-HAART era, and after 1996, in the HAART era after protease inhibitors became available for treatment [96]. A study by Liljерening et al. found that patients with CD4 <200/mm2 had higher factor VIII and fibrinogen concentrations and lower protein S concentrations, perhaps explaining some of the difference in thrombosis rates [97]. Other factors underlying thromboembolic events in HIV-infected patients are discussed in a previous section of this paper.

Pulmonary hypertension is significantly increased in HIV infected patients compared to the general population, with an incidence of around 0.5% reported in 1991 [98]. The same incidence (0.46%) was found in a 2008 study, thus refuting the hypothesis that the incidence had decreased since the introduction of HAART [99, 100]. Though HAART improved mortality in HIV-infected patients with pulmonary hypertension in a prospective study of the Swiss HIV Cohort, the median survival was poor at 2.7 years from diagnosis [101]. Therefore, pulmonary hypertension portends a poorer prognosis in HIV-infected patients, despite HAART therapy [102].

The rates of endocarditis are similar among HIV-infected patients with shared risk factors, such as injection drug use, and non-HIV-infected individuals. HIV per se does not seem to be a risk factor for endocarditis, though mortality may be higher for those with CD4 counts under 200/mm3 [85, 103].

Finally, cardiac neoplasms are a rare complication of AIDS. B cell lymphomas can be primary cardiac lymphomas or part of disseminated disease. Kaposi’s sarcoma can rarely invade the heart in disseminated disease. Both of these neo-
plasmas are more common in HIV-infected than in HIV-uninfected patients [85].

**PRIMARY CARE AND CO-MORBID CONDITIONS ASSOCIATED WITH ARVS**

Because of the high rate of morbidity and mortality associated with cardiovascular disease in HIV-infected patients, it is important to identify those at risk so they can be targeted for aggressive risk-management. Risk factors for cardiac disease include increased age, male sex, smoking, elevated LDL-C, low HDL-C, hypertension, and the presence of diabetes or peripheral vascular disease [104]. HIV-infected men have a greater number of these traditional CAD risk factors compared to HIV-uninfected controls [105]. The Framingham Risk Score (FRS) has been validated as a way to quantify 10-year coronary heart disease risk based upon age, sex, total cholesterol (TC), HDL-C, smoking status, and systolic blood pressure in the general population [106]. A link to the 10-year risk calculator can be found at http://www.nhlbi.nih.gov/guidelines/cholesterol. When applied to the HIV-infected population in the D:A:D study, the FRS slightly underestimated the number of CHD events for patients on ARV therapy, but in ARV-naive patients, it overestimated the risk [107]. This may be for reasons including the direct effect of HIV on the endothelium, an effect of PI therapy apart from its metabolic effects (via up-regulation of CD36, which is a receptor on macrophages increasing cholesterol uptake and promoting foam cell formation and atherosclerosis [108]), an increased differential effect of cardiac disease risk factors on HIV patients, or the fact that in general, we are applying the Framingham study to a younger HIV-infected population than the one in which it was developed [109]. Since the FRS estimates 10-year cardiovascular risk, it may be too short to represent the lifetime risk of younger or middle-aged HIV-infected patients [110]. A new prediction tool developed from the D:A:D study, which also includes family history, the TC/HDL-C ratio, the presence of diabetes, and the duration of exposure to PIs, performed better than the FRS in predicting CHD in this cohort [109, 111].

Given the higher prevalence of subclinical atherosclerosis in HIV-positive individuals discussed above, carotid ultrasoundography can be considered as a way to assess cardiovascular risk in this population. Maggi et al. found that carotid vascular wall lesions were associated with PI therapy, and recommended screening ultrasonography for this group to guide cardiovascular risk management [112]. Another means of assessing cardiovascular risk is the high-sensitivity C-reactive protein (CRP). This has been associated with traditional cardiovascular risk factors in HIV-infected patients, including waist-to-hip ratio, fasting glucose, NNRTI therapy, PI therapy, and the metabolic syndrome [113]. Elevated CRP is a marker of visceral fat accumulation and predicts higher cardiovascular mortality in HIV-infected women [114]. Reingold et al. found that male patients with HIV monoinfection had an 88% higher CRP level than controls, while there was no difference in women [114]. However, HCV co-infection was associated with 50% lower CRP levels. CRP levels were strongly correlated with visceral adipose tissue and subcutaneous adipose tissue. Of interest is that CRP levels did not correlate with CD4 count or HIV viral load, or with ARV therapy, though other studies have found an association between CRP and ARV therapy [115]. In this study, by Masiá et al., CRP elevation of 0.3 mg/dL or greater occurred in fully 40% of HIV-infected patients studied. CRP levels can help stratify cardiovascular risk in moderate-risk patients in the general population, and may have a role to play in risk stratification in HIV-infected patients as well.

Smoking has been identified as the most important modifiable CAD risk factor in HIV-infected patients [116]. In the SIMONE study, a national Italian study of HIV-infected patients, smoking was the main contributor to coronary heart disease (CHD) risk in HIV-infected patients [117]. HIV-infected patients have been found to have high rates of smoking in several studies, including in a combined analysis of the MACS study and the Women’s Interagency HIV Study (WIHS), which found about 35-40% of HIV-infected patients were smokers [105]. Among men in this study, HIV-infected patients had higher smoking rates than in HIV-negative controls. In the D:A:D study, more than 50% of the patients were former or current smokers, and they had double the risk of MI [118]. In the SIMONE study, the smoking prevalence was 60% [119]. In the Swiss HIV Cohort the prevalence of current smokers was 47.6% in 2006 [120]. A discussion of smoking cessation methods is beyond the scope of this paper, but various programs have been found to be effective in the HIV-infected population [121, 122].

Diabetes is also an important risk factor for CAD; like smoking, it has a higher prevalence in HIV-infected patients than in the general population. In the Multicenter AIDS Cohort (MACS) study, the incidence of diabetes in HIV-infected men on HAART was more than four times that of HIV-seronegative men [123]. The metabolic syndrome has a similar prevalence of approximately 25% among HIV-infected and HIV-uninfected controls, but a higher proportion of HIV-infected patients with the metabolic syndrome have diabetes [124]. Lifestyle therapy is important in the treatment of metabolic syndrome and diabetes. The Diabetes Prevention Program found that patients with impaired glucose tolerance who underwent a diet and exercise program were 41% less likely to develop the metabolic syndrome [125]. Though this study did not specifically study HIV-positive patients, the results should be applied to all patients. Glycemic goals, according to the American Diabetes Association (ADA) are a HbA1C of ≤7% for most patients, with an option of tighter control to 6% for selected patients [126].

As well as addressing cardiac risk factors in diabetics, diabetics with HIV infection who are over age 40 or have any cardiac risk factors should all receive low-dose aspirin therapy in accordance with ADA recommendations. There is no known contraindication to ASA therapy in HIV-positive individuals. In a study of the management of diabetes in HIV-infected individuals, only 5% were receiving the recommended ASA therapy [127]. Along the same lines, according to the American Heart Association, aspirin therapy should be recommended for any patient with an FRS of 10% or greater as primary prevention of MI and stroke, and the data from the D:A:D study, among others, suggests that HIV-infected patients have high levels of cardiac risk and disease, and should have the same therapeutic interventions to prevent CAD as HIV-uninfected patients [128].
Hypertension in HIV-infected individuals should be treated according to JNC 7 guidelines [129]. Updated hypertension guidelines (JNC 8) are scheduled to be released in 2019. Anyone with a blood pressure reading of >140/90 mmHg or a FRS ≥10% should be treated with a goal blood pressure of <130/80 mmHg. Lifestyle modifications are recommended for any HIV-infected patient with hypertension, including weight loss if appropriate, sodium restriction and healthy diet, exercise, smoking cessation, and moderation in alcohol consumption. If systolic blood pressure is ≥160 mm Hg, or diastolic blood pressure is ≥100 mm Hg, then treatment should be started with 2 drugs simultaneously. Thiazide diuretics are first-line therapy unless there is a compelling indication for alternative treatment; such as beta-blockers (use with caution with atazanavir) or angiotensin-converting enzyme (ACE) inhibitors for heart failure; beta-blockers or calcium-channel blockers (start with low doses of amlodipine, nifedipine, and verapamil in HIV-infected patients) for ischemic heart disease; ACE inhibitors or angiotensin receptor blockers (ARBs) for chronic kidney disease and diabetes; and ARBs or ACE inhibitors for left ventricular hypertrophy. Hypertension management is an important component of lowering overall risk of cardiovascular disease including stroke and MI in HIV-infected patients.

Lifestyle changes are the first line of therapy for ARV-associated dyslipidemia and metabolic syndrome. A 6-month intensive lifestyle modification program was able to significantly reduce waist circumference, systolic blood pressure, hemoglobin A1C, and lipodystrophy, but not serum lipid levels, in HIV-infected patients with the metabolic syndrome [130]. Dietary and exercise interventions were successful in lowering cholesterol levels 11% in one study [131]. Diet and exercise reduced TC by 18% and TGs by 25% in another study [132]. In a comparison of fish oil supplementation versus diet and exercise, triglyceride levels were decreased 19.5% in the fish oil plus diet and exercise group versus only 5.7% in the diet and exercise group [133].

Guidelines for the management of CHD risk factors in HIV-infected patients were published in 2003, and do not differ significantly from those for HIV-uninfected patients, and are based on the Adult Treatment Panel III (ATP III) guidelines from 2001 [9]. An update of the ATP III guidelines was published in 2004, and the ATP IV guidelines are expected to be released in 2009 [134]. According to the ATP III guidelines and update, a fasting lipid profile should be done on all patients before initiating ARVs, and 3-6 months after starting a new ARV regimen. It can then be done yearly if no lipid abnormalities are detected. If a patient has triglyceride levels greater than 200 mg/dL prior to initiating ARV therapy, a lipid panel should be done within 1 to 2 months after starting ARV therapy, as TGs greater than 500 mg/dL put patients at increased risk of pancreatitis and require prompt treatment. LDL-C is the primary target for lipid-lowering therapy, unless TGs are found to be >500 mg/dL, in which case therapy with a fibrate should be started preferentially.

The lipid goals are based upon Framingham risk factors, and in general should be applied equally to HIV-infected and HIV-uninfected patients. Patients considered high risk are those with a CHD risk equivalent including a previous cardiovascular event, diabetes, cerebrovascular disease or peripheral vascular disease, or, two or more cardiac risk factors (total cholesterol ≥240 mg/dL, systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, and smoking) with a 10-year calculated CHD risk of >20%. In high risk patients, the treatment goal is an LDL-C less than 100 mg/dL. If the LDL-C is >100 mg/dL, lifestyle changes should be initiated and drug therapy considered. If the LDL-C is already less than 100 mg/dL, drug therapy with an LDL-C lowering drug should also be considered. However, if the patient is very high-risk, including those with acute coronary syndrome, or known cardiovascular disease combined with diabetes, metabolic syndrome, poorly controlled risk factors, or ongoing tobacco use, the LDL-C goal may be set to less than 70 mg/dL. If a patient is at moderately high risk, with ≥2 risk factors, and a calculated risk between 10-20%, the LDL-C treatment goal is < 130 mg/dL, with initiation of drug therapy if the LDL-C is > 130 mg/dL. For moderately high risk patients, there is an option to set the treatment goal at an LDL-C < 100 mg/dL, and to use drug therapy if the LDL-C is between 100 and 129 mg/dL. Another metric for LDL-C goals for high and moderately high risk patients is to reduce the LDL-C by 30%, regardless of starting LDL-C level. For those patients with a moderate risk (FRS is <10% and 2+ risk factors), drug therapy should be considered at an LDL-C of 160 mg/dL. If the patient only has 0-1 risk factors then drug therapy would not be recommended until the LDL-C level reaches 190 mg/dL [134]. No specific goal for HDL-C has been set, though some trials have found treating patients with low HDL-C and high triglycerides reduces the risk of CHD. Nicotinic acid has been found to raise HDL-C and lower CHD risk. Another lipid target set forth for patients with TGs>200 is non-HDL-C, which is a measure of VLDL and LDL-C. This target is 30 mg/dL higher than the LDL-C goal. It takes into account remnant lipoproteins in patients with high TGs [134].

Consideration should also be given to changing antiretroviral agents prior to the initiation of lipid-lowering medications. The benefits of switching ARV regimens are proven but appear to be modest compared to the use of lipid-lowering agents, probably because all ARV regimens affect lipid metabolism to some degree. A one year study of HIV-infected adults on HAART including a PI with mixed hyperlipidemia of TG >200 mg/dL and TC >250 mg/dL, compared switching the PI to an NNRTI versus adding a statin [135]. Initiation of pravastatin or bezafibrate was more effective than switching to nevirapine or efavirenz in lowering TC, LDL-C, and TGs, and in raising HDL-C. The percentage of patients who reached normal cholesterol levels was 56% in the pravastatin arm, 42% in the bezafibrate arm, 24% in the nevirapine arm, and 12% in the efavirenz arm. Therefore lipid management was more effective after adding lipid-lowering therapy than switching ARV regimens. In the Switch to Another Protease Inhibitor (SWAN) study, patients on ritonavir boosted or unboosted PIs switched to...
unboosted atazanavir, or ritonavir boosted atazanavir if receiving tenofovir [136]. Switching therapy to atazanavir was successful in lowering TC and TG. Virologic rebound was lower in patients switched to an atazanavir-containing regimen (7% versus 16% kept on their old regimen), confirming that it does not put suppression of HIV viral replication in jeopardy to do so. In general, if a patient has sustained viral suppression, then switching ARV therapies to reduce lipid levels is safe [137]. Switching ARVs has also improved insulin resistance. Switching from indinavir/ritonavir to atazanavir/ritonavir improved insulin resistance in all 9 HIV-infected men evaluated in one study [138].

For patients with elevated LDL-C or with elevated non-HDL-C levels along with TG levels that are 200-500 mg/dL, therapy with a statin is recommended as first line treatment [9]. Fibrates are recommended if the serum TGs are >500 mg/dL. The statins with the lowest potential for interaction with antiretroviral therapy are pravastatin, at a starting dose of 20-40 mg daily, and fluvidastatin, starting at 20 mg daily. Low-dose atorvastatin (10 mg) is also a safe starting dose. Pravastatin cannot be used in combination with darunavir, because darunavir increases the AUC of pravastatin by 81% [139]. Low-dose atorvastatin (10mg daily), or rosvastatin (10-40 mg daily), though both acceptable, may require closer monitoring because of increased drug interactions. Rosuvastatin at 10 mg daily was effective in reducing total cholesterol and triglycerides in HIV-infected patients with PI-induced hyperlipidemia [140]. However, rosuvastatin should be used with caution as the AUC and Cmax are increased 2.1 to 4.7-fold in combination with lopinavir/ritonavir in healthy volunteers [141]. For all patients on PIs, statins should be started at the lowest dose, and increased as needed according to the therapeutic response and toxicity monitoring. Simvastatin and lovastatin are contraindicated in patients taking PIs because blood levels are increased significantly by PIs [27], and concomitant use has been associated with rhabdomyolysis [142-147]. All statins are safe with the NRTIs and NNRTIs, though statin blood levels may be reduced with NNRTIs. The pharmacokinetics of raltegravir with pravastatin is currently being studied, but as raltegravir does not undergo metabolism by the CYP450 system, drug interactions should be minimal. Maraviroc is metabolized through the CYP3A isoform, but does not inhibit the CYP450 system, so would not be expected to raise statin levels, but no data is available [148].

It has been difficult to reach all cholesterol goals in HIV-infected patients with statins alone [136, 149, 150]. If further drug therapy is needed, ezetimibe and fibrates are safe with all ARVs, with no and minimal interactions, respectively. Fibrac acid derivatives may modestly reduce LDL-C levels in patients with normal TGs, but in patients with elevated TGs, LDL-C levels rise slightly [151]. Three fibrates, bezafibrate, gemfibrozil, and fenofibrate, were compared in a randomized trial for the management of ARV-associated hypertriglyceridemia and hypercholesterolemia [152]. All drugs performed similarly, with reductions of 41% in TGs and 23% in TC. Combination therapy with fenofibrate and pravastatin was also studied in HIV subjects with LDL-C >130 mg/dL and TG >200 mg/dL [151]. Each drug was initiated singly, and then the other was added when lipid level thresholds were not met. Of those on fenofibrate who then added pravastatin, 16% achieved National Cholesterol Education Program III (NCEP III [153]) goals of LDL-C <100 mg/dL and TG <200 mg/dL for patients with two or more cardiac risk factors, while 5% of those who initiated pravastatin first and then added fenofibrate did. This suggests that sequential therapy starting with fenofibrate and then pravastatin is preferable, but few patients reached all target lipid levels with the combination. One retrospective study found the addition of statins and fibrates allowed more HIV patients taking ARVs to reach their cholesterol goals, but the success rates were also relatively low with less than 20% reaching NCEP II goals [150]. Caution must be used in combining fibrates with certain statins because of the increased risk of rhabdomyolysis [11, 147].

Alternative lipid-lowering therapies to statins are an area of active study in HIV. A study of combination fish oil 3 g twice daily and fenofibrate 160 mg once daily for HIV patients not achieving TGs <200 mg/dL with either agent alone found that the combination provided improved TG-lowering effects over either drug alone, achieving the goal in 23% of patients [154]. Ezetimibe has also been studied as an addition to lipid management in HIV-infected individuals. It was given to patients who had an LDL>130 mg/dL despite treatment with pravastatin [155]. At 6 weeks there were significant falls in TC, LDL-C, and TGs, but these benefits diminished by week 24. HDL-C levels increased throughout the study. Ezetimibe monotherapy has also been studied in HIV-infected patients [156]. Patients with an average baseline LDL-C of 121 mg/dL were started on ezetimibe or placebo. LDL-C decreased an average of 12% for patients receiving ezetimibe versus 3% for placebo. There were no significant changes in TGs or HDL-C.

Niacin is not a first-line choice for lipid therapy because of its propensity to cause insulin resistance [9]. However, it was tolerated when used for treatment of low HDL-C levels in HIV-infected subjects, and was associated with a significant decrease in intra-abdominal fat [157]. Bile-sequestering resins should be avoided in HIV-infected individuals because they may be associated with increased triglyceride levels and their effect on antiretroviral absorption is unknown [9].

**INTERVENTIONAL CARDIOLOGY IN HIV-INFECTED PATIENTS**

Solid organ transplantation has now become a successful reality in HIV-infected patients. The first successful heart transplant in an HIV-infected individual was performed in 2001, in a patient with AIDS and a history of multiple opportunistic infections [158]. The patient lived for 3.5 years post-transplant. However, the cause of death was not reported [159]. A second heart transplant was reported in 2003 in a patient with normal CD4 counts and an undetectable HIV viral load [160, 161]. The patient had an uneventful recovery. Another patient who acquired HIV from blood products transfused after her heart transplant has continued to do well. Another patient who acquired HIV from blood products transfused after her heart transplant has continued to do well with no major complications 10 years after her transplant [162]. A number of successful liver and kidney transplants have been performed in HIV-positive patients (19 and 26, respectively, in one review), with short-term survival rates...
comparable to non-HIV-infected recipients [163]. Though no statement has been made by national transplant organizations regarding transplant in HIV-positive patients, there is a growing consensus that HIV infection should not be an absolute contraindication to solid organ transplantation. It has been suggested that HIV positive transplant candidates should have undetectable viral loads, normal CD4 counts, and no history of opportunistic infections [160]. However, because opportunistic infections can now be controlled with antimicrobials and immune reconstitution following HIV treatment, this is no longer felt to be an absolute contraindication, and only opportunistic infections with no reliable treatment, such as progressive multifocal leukoencephalopathy, chronic cryptosporidiosis, and drug-resistant fungal infections should be contraindications for transplant [164].

Reports of percutaneous coronary intervention (PCI) have provided mixed results. An observational study of 50 HIV+ and 50 HIV- patients undergoing PCI with the majority receiving stents, and all patients treated with aspirin and clopidogrel at discharge, found no deaths and no difference in restenosis rates (14% vs 16%, p = 0.78) at 321 days mean follow-up [165]. However, 5 of 12 HIV infected patients followed after stenting in another study had in-stent restenosis after a mean follow-up of 16 months [166]. Of 24 HIV+ patients admitted with acute myocardial infarction in another study, 20% had reinfarction after discharge, and 43% of those who had PCI, ended up requiring target vessel revascularization [167]. There is a report of late in-stent restenosis in an HIV-positive patient with a drug-eluting stent 23 months after placement, and lifelong aspirin and clopidogrel therapy have been recommended [168].

A study of 27 HIV infected patients undergoing coronary artery bypass graft (CABG) compared to case controls found equal rates of major adverse cardiac events at 30 days, but increased need for revascularization at a mean follow-up of 41 months (42% versus 25%, p = 0.03) [169]. Another series of 37 patients looking at outcomes of cardiac surgery including CABG and valvular replacement found acceptable outcomes of freedom from class III angina or heart failure symptoms, MI, death, and repeat revascularization of 81% of patients at 3 years [170]. However, a note of caution was sounded in mentioning 6 needlestick injuries in these 37 surgeries, none of which resulted in HIV seroconversion. In conclusion, it appears that revascularization techniques including PCI and CABG produce good clinical outcomes in HIV+ patients, though a higher need for subsequent revascularization procedures has been documented.

CONCLUSIONS

It is likely that cardiologists will see HIV infected patients in consultation for medical or interventional management of CV associated disorders. As the HIV population in western countries ages, it is also likely that the prevalence of CV disease in the HIV infected population will increase and cardiologists will have to balance HIV care with management of other co-morbid conditions commonly associated with HIV such as hypertension, diabetes, and hyperlipidemia. Successful management requires understanding HIV specific issues, and coordination of care with the HIV specialist.

REFERENCES

[1] 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 Dec 18; 41(RR-17): 1-19.
[2] UNAIDS Joint United Nation Programme on HIV/AIDS.
[3] HIV/AIDS Statistics and Surveillance. Centers for Disease Control.
[4] US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://www.aidsinfo.nih.gov/guidelines. Accessed March 15th, 2008 2008.
[5] Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36(Suppl 2): 247-51.
[6] Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74(5): 1045-52.
[7] Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass B. J Clin Endocrinol Metab 1993; 76(6): 1423-7.
[8] White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77(3): 158-73.
[9] Dube MP, Stein JH, Abeg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37(5): 613-27.
[10] Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42(2): 81-92.
[11] Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32(3): 247-60.
[12] Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol 2007; 18(5): 561-5.
[13] Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease-inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351(9119): 1881-3.
[14] Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 2: S135-42.
[15] Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007; 45(Suppl 1): S19-26.
[16] Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21(18): 2445-53.
[17] Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hyperadiponectinemia. Diabetes Care 2007; 30(1): 113-9.
[18] Ledergerber B, Furrer H, Rickebusch M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45(1): 111-9.
[19] De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D: A: D study. Diabetes Care 2000; 23(6): 1224-8.
[20] Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc 2005; 97(8): 1088-92.
[21] Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275(27): 20251-4.
[22] Nolte LA, Yarasheki KE, Kawakana K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and
contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50(6): 1397-401.

[23] Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18(16): 2137-44.

[24] Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20(14): 1813-21.

[25] Brown TT, Li X, Cole SR, et al. Cusomative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19(13): 1375-83.

[26] Fleischer AL, Weisbrod DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292(6): E1666-73.

[27] Chuck SK, Penza SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002; 1(1): 5-17.

[28] US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/guidelines. Accessed March 15th, 2008.

[29] Liverpool HIV Pharmacology Group. HIV Drug Interactions.

[30] Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS 2007; 21(12): 1469-51.

[31] Teleni A, Zanger UM. Pharmacogenetics of anti-HIV drugs. Annual review of pharmacology and toxicology 2008; 48: 227-56.

[32] Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007; 17(9): 755-64.

[33] Hsue PY, Lo JC, Franklin A, Bolger AF, et al. Progression of athe- roclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109(13): 1603-8.

[34] Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185(4): 456-62.

[35] van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tk PP. Systemic inflammation as a risk factor for atherosclerosis. Rheumatology (Oxford) 2008; 47(1): 3-7.

[36] Torre D. Nitric oxide and endothelial dysfunction in HIV type 1 infection. Clin Infect Dis 2006; 43(8): 1086-7.

[37] Paladugu R, Fu W, Conklin BS, et al. Hypertriglyceridemia in the Multicenter AIDS Cohort Study. AIDS 2002; 16(17): 2155-64.

[38] Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-seronegative healthy adults. AIDS 2004; 18(16): 2137-44.

[39] Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98(16): 10142-7.

[40] Hsue PY, Waters DD. What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation 2005; 112(25): 3947-55.

[41] Solages A, Vira IA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42(9): 1325-32.

[42] Stein JH, Klein MA, Bellahmneur JL, et al. Use of human immuno- nedeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104(3): 257-62.

[43] Jiang B, Hebert VY, Zavech JJ, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006; 42(4): 391-5.

[44] de Gaetano Donati K, Rabagliarii L, Iacovielll L, Cauda R. HIV infection, HAART, and endothelial cell dysfunction: current perspectives. Lancet Infect Dis 2004; 4(4): 213-22.

[45] Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31(3): 787-97.

[46] Triaent NA, Lee H, Hidagcin C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocriol Metab 2007; 92(7): 2506-12.

[47] Obel N, Thomsen HJ, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44(12): 1625-31.

[48] Klein D, Harley LB, Quesnberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV infection? J Acquir Immune Defic Syndr 2002; 30(5): 471-7.

[49] Hobart SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360(9347): 1747-78.

[50] Illoee UH, Yuan Y, L’talien L, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6(1): 37-44.

[51] Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479-86.

[52] Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20(15): 1941-50.

[53] Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-93.

[54] Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial in- farction. N Engl J Med 2007; 356(17): 1723-35.

[55] Stein JH. Cardiovascular risks of antiretroviral therapy. N Engl J Med 2007; 356(17): 1773-5.

[56] Sabin C, Worm S, Weber, R. Do thymidine analogues abacavir, didanosine and lamivudine contribute to the risk of myocardial in- farction? The D:A:D study. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 957c 2008 Feb.

[57] Kaplan RC, Tien PC, Lazar J. Antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 357(7): 715; author re- sponse 717-6.

[58] El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral therapy. N Engl J Med 2007; 356(17): 1043-27.

[59] El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Ar- duino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 355(22): 2283-96.

[60] Miller KL. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 139 2008 Feb.
[68] Calmy A, Nguyen A, Montecucco, F. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 140 2008 Feb.

[69] Papasavvas E, Azzouz, L, Pirotti, M. Acute viral rebound as a result of structured treatment interruptions in chronically HIV-1-infected subjects: A pathway to cardiovascular risk? Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 964 2008 Feb.

[70] Bozette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348(8): 702-10.

[71] Mercie P, Thiebaut R, Aurillac-Lavignolle V, et al. Carotid intima-media thickness: an early marker of subclinical atherosclerosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005; 40(3): e172-80.

[72] Jerico C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37(3): 821-7.

[73] Maggi P, Serio G, Efpiani G, et al. Premature lesions of the carotid vessels in HIV-infected patients treated with protease inhibitors. AIDS 2000; 14(16): F123-8.

[74] Coll B, Parra S, Alonso-Villaverde C, et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007; 38(9): 2477-84.

[75] Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocytotropic chemokine receptor-1 allele. Circulation 2004; 110(15): 2204-9.

[76] Hseu PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20(18): 2275-83.

[77] McComsey GA, O’Riordan M, Hazen SL, El-Bejani D, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21(8): 921-7.

[78] Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21(10): 1375-9.

[79] Currier JS, Kendall MA, Zachrins K, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors over-shadow impact of protease inhibitor exposure. AIDS 2005; 19(9): 927-33.

[80] Coll B, Alonso-Villaverde C, Masana L. Carotid intima-media thickness course in HIV-infected patients: beyond classical cardiovascular risk factors. AIDS 2007; 21(14): 1899-90.

[81] Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 1993; 71(11): 955-8.

[82] Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotoxic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994; 24(4): 1025-32.

[83] Pugliese A, Isnarid D, Saini A, Scarabelli T, Raddino R, Torres D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40(3): 282-4.

[84] Mayosi BM, Wiswongse CS, Nokhele M, et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect Dis 2006; 6: 2.

[85] Nitsche M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112(23): 3602-7.

[86] Saber AA, Aboualain A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67(7): 645-7.

[87] Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15(6): 311-20.

[88] Fultz SL, McGinnis KA, Skanderson M, Raghi MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus infection and mortality in veterans. Am J Med 2004; 116(6): 420-3.

[89] Liifering WM, Sprenger HG, Geeg RR, van der Meulen PA, van der Meer J. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008; [Epub ahead of print].

[90] Speich R, Jenni R, Opravil M, Pfib M, Rius EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100(5): 1268-71.

[91] Stibon O, Lascoz-Coumel C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. J Am Respir Crit Care Med 2008; 177(1): 108-13.

[92] Barnett CF, Hseu PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemia and HIV infection. JAMA 2008; 299(3): 324-31.

[93] Zuber JP, Calmy A, Evison JM, et al. Predicting the risk of coronary artery disease in HIV-infected patients: comparison with observed events in the D: A: D risk equation. J Acquir Immune Defic Syndr 2005; 38(8): 1178-85.

[94] Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007; 28(1): 1-22, vii.

[95] Barbarin G, Barbarin G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003; 17(Suppl 1): S1-34.

[96] Wilson PW, D’Agostino RB, Levy D, Belanger A, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.

[97] Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted cardiovascular disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45(8): 1074-81.

[98] Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk prediction and lifetime risk for coronary heart disease. Am J Cardiol 2004; 94(1): 20-4.

[99] Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D: A: D Study. HIV Med 2006; 7(4): 218-30.

[100] Dressman J, Kinzer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111(3): 389-97.

[101] Friis-Moller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45(8): 1082-4.

[102] Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005; 38(2): 115-7.

[103] Friis-Moller N TR, Reiss P, et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D: A: D risk equation. Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections 2007; Los Angeles, California. Abstract 808.
with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41(10): 1496-504.

134. Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-39.

135. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia. AIDS 2005; 19(10): 1051-8.

136. Gallet J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44(11): 1484-92.

137. Dreehlers H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35(10): 1219-30.

138. Busi AJ, Bedimo R, Margolis DM, Hirdin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008; 56(2): 539-44.

139. Sekar VJ S-GS, Marien K. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent gemfibrozil 8th International Workshop on Pharmacology of HIV Therapy, Budapest 2007 August 16-18; Ab-stract 55.

140. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19(10): 1103-5.

141. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Moody DW. Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. J Acquire Inimm Defic Syndr 2006; 43(1): 570-8.

142. Aboulafia DM, Johnston RA. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Pa-tient Care STDs 2000; 14(1): 13-8.

143. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002; 112(6): 505.

144. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 59(8): 728-30.

145. Hare CB, Xu MP, Grijpstra C, Lampiris HW. Simvastatin-nelfinavir interaction implied in rhabdomyolysis and death. Clin Infect Dis 2002; 35(10): e111-2.

146. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after con-comitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDs 2003; 17(5): 207-10.

147. Mastroianni CM, d’Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 2001; 15(6): 820-1.

148. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2008: 1-128.

149. Gatell. SWAN: Final 48-week Lipoit Results of Switch to ATV 10th European AIDS Conference 2005; Abstract #PS1/1.

150. Visnegarwala F, Maldonado M, Saja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipide-mia associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49(4): 283-90.

151. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the eficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities. AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21(9): 757-67.

152. Calza L, Manfredi R, Chiado F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. In-fection 2002; 30(1): 26-31.

153. Executive Summary of The Third Report of The National Choles-terol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
[154] Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47(4): 459-66.

[155] Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20(17): 2159-64.

[156] Wohl D, Hsue P, Richard S, et al. Ezetimibe’s Effects on the LDL Cholesterol Levels of HIV-infected Patients Receiving HAART 14th Conference on Retroviruses and Opportunistic Infections 2007; Abstract 39.

[157] Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002; 16(13): 1785-9.

[158] Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348(23): 2323-8.

[159] Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients: are we there yet? J Heart Lung Transplant 2007; 26(2): 103-7.

[160] Bisleri G, Morgan JA, Deng MC, Mancini DM, Oz MC. Should HIV-positive recipients undergo heart transplantation? J Thorac Cardiovasc Surg 2003; 126(5): 1639-40.

[161] Morgan JA, Bisleri G, Mancini DM. Cardiac transplantation in an HIV-1-infected patient. N Engl J Med 2003; 349(14): 1388-9; author reply -9.

[162] Gupta S, Markham DW, Mammen PP, et al. Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant. Am J Transplant 2008 Feb 19.

[163] Roland ME, Adey D, Carlson LL, Terrault NA. Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDSTransplant 2003; 17(10): 501-7.

[164] Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007; 84(5): 563-71.

[165] Boccara F, Teiger E, Cohen A, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart 2006; 92(4): 543-4.

[166] Segev A, Cantor WJ, Strauss BH. Outcome of percutaneous coronary intervention in HIV-infected patients. Catheter Cardiovasc Interv 2006; 68(6): 879-81.

[167] Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163(4): 457-60.

[168] Stollberger C, Armbruster C, Gmeinhart B, Finsterer J. Thrombosis of a drug-eluting stent after almost 2 years in an HIV-infected patient. AIDSTransplant 2007; 21(8): 1064-6.

[169] Boccara F, Cohen A, Di Angelantonio E, et al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. Curr HIV Res 2008; 6(1): 59-64.

[170] Trachiotis GD, Alexander EP, Benator D, Ghargozloo F. Cardiac surgery in patients infected with the human immunodeficiency virus. Ann Thorac Surg 2003; 76(4): 1114-8; discussion 8.